Anavex Life Sciences Corp (AVXL)

[Investor2014]

Dado,

In comparison to A2-73, I am curious how you rate GW Pharmaceuticals EPIDIOLEX cannabinoid product candidate for severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS), as well as Zogenix ZX008.

Are we further upstream with A2-73 in addressing the cause of epilepsy than these two seemingly promising new late stage epilepsy candidates?

Thanks in advance for your insights!